NTHI
MaterialsNeOnc Technologies Holdings Inc
$5.31+0.32 (+6.41%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NTHI Today?
No stock-specific AI insight has been generated for NTHI yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$134M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume87K
Avg Volume (10D)—
Shares Outstanding25.3M
NTHI News
20 articles- NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data CatalystsYahoo Finance·May 5, 2026
- New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)Yahoo Finance·Apr 18, 2026
- NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial ResultsYahoo Finance·Apr 14, 2026
- NeOnc Provides Business Update and Reports Q4 2025 Financial ResultsYahoo Finance·Apr 1, 2026
- NeOnc Technologies Appoints David Choi as Chief Accounting OfficerYahoo Finance·Mar 13, 2026
- Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)Yahoo Finance·Mar 12, 2026
- NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ETYahoo Finance·Mar 4, 2026
- NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and ToxicityYahoo Finance·Feb 27, 2026
- New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin AmericaYahoo Finance·Feb 21, 2026
- New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)Yahoo Finance·Feb 14, 2026
- New to The Street(R) Airs Tonight on Bloomberg Television Across the U.S., MENA & Latin AmericaYahoo Finance·Feb 7, 2026
- New to The Street Broadcasts Today on Bloomberg Across the U.S., MENA, and Latin AmericaYahoo Finance·Jan 31, 2026
- NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital ManagementYahoo Finance·Jan 30, 2026
- Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)Yahoo Finance·Jan 10, 2026
- New to The Street Airs Tonight on Bloomberg Television - Show No. 712 Sponsored Programming Spotlighting Public and Private Market InnovatorsYahoo Finance·Jan 3, 2026
- New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg TelevisionYahoo Finance·Dec 27, 2025
- New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc ($NTHI), Metaterra Holdings Inc., CISO Global ($CISO), and NRx Pharmaceuticals ($NRXP)Yahoo Finance·Dec 20, 2025
- NeOnc Technologies Reports Updated Clinical ResultsYahoo Finance·Dec 15, 2025
- Insider Buys Additional US$185k In NeOnc Technologies Holdings StockYahoo Finance·Dec 2, 2025
- NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain TumorsYahoo Finance·Dec 1, 2025
All 20 articles loaded
Price Data
Open$5.01
Previous Close$4.99
Day High$5.38
Day Low$4.70
52 Week High—
52 Week Low—
Fundamentals
Market Cap$134M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume87K
Avg Volume (10D)—
Shares Outstanding25.3M
About NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—